MedCAC Review Of ESAs In Renal Disease To Help Determine Whether NCD Is Needed, CMS Official Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The Medicare Evidence Development and Coverage Advisory Committee reviewed the safety of erythropoiesis stimulating agents in chronic kidney disease at a March 24 meeting.